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Abstract Tumor necrosis factor (TNF) induces hepatitis when
injected in human beings or in rodents. The molecular mechanism
by which TNF induces hepatic distress remains largely unknown,
although induction of apoptosis of hepatocytes appears to be an
essential step. In order to increase the therapeutic value of TNF,
we have studied the protective activity of several molecules and
found that four chemically totally different substances confer
significant protection in the model of TNF-induced lethal
hepatitis in mice sensitized with D-(+)-galactosamine (GalN),
but not in mice sensitized with actinomycin-D (ActD) or against
anti-Fas-induced lethal hepatitis. Verapamil, a calcium-channel
blocker, tannic acid, picotamide, a thromboxane A2 receptor
antagonist, and K76COOH, an inhibitor, amongst others, of
complement, protected significantly against induction of leth-
ality, release of the liver-specific enzyme alanine aminotransfer-
ase (ALT) and induction of apoptosis in the liver after TNF/
GalN, except for K76COOH, which paradoxically increased
ALT values after challenge, and which also protected against
TNF/GalN in complement-deficient mice. The data suggest that
activation of platelets and neutrophils, as well as induction of
inflammation occur in the TNF/GalN model, but not in the TNF/
ActD or anti-Fas models, in which direct induction of apoptosis
of hepatocytes may be more relevant. The protective activity of
the drugs may lead to an increase in therapeutic value of TNF.
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1. Introduction
The powerful anti-tumor activity of tumor necrosis factor
(TNF), combined with interferon-Q and melphalan, is cur-
rently used to cure metastatic melanomas and sarcomas
with a very high e⁄ciency, albeit only in a system of loco-
regional administration [1^3]. Leakage of TNF (and interfer-
on) into the general circulation leads to a life-threatening sys-
temic in£ammatory response syndrome (SIRS), characterized
by a drop in blood pressure and hepatotoxicity, both of which
were considered, after clinical trials with human volunteers, as
dose-limiting toxicities [4]. Understanding the mechanism of
induction of liver toxicity by TNF may lead to an increase in
the therapeutic value of TNF, but also to a more e⁄cient
treatment of hepatic disorders in which TNF has proven to
play a pivotal role, such as alcoholic hepatitis [5,6].
Several models have been used to study the mechanisms of
experimental lethal hepatitis in mice: (a) TNF in combination
with D-(+)-galactosamine (GalN), (b) TNF with actinomycin-
D (ActD), or (c) anti-Fas. GalN is a hepatotoxin that specif-
ically inhibits transcription and translation in hepatocytes [7].
In combination with GalN, TNF becomes lethal at low doses
and causes massive apoptosis of hepatocytes [8,9]. A similar
liver damage is obtained when TNF is combined with the
general transcription inhibitor ActD [9,10] or when anti-Fas
is administered [9,11]. In all three models, the animals suc-
cumb relatively short after the challenge, exhibiting extreme
apoptosis and secondary necrosis in the liver. However, sev-
eral di¡erences were found between the three models, suggest-
ing that the TNF/GalN model is more complex than the other
two models, and involves activation, amongst others, of serine
proteases and platelet-activating factor (PAF) [9,12,13]. In the
current paper, we describe our e¡orts to further investigate
the mechanism of induction of lethal hepatitis by TNF in
GalN-sensitized mice. We start from the hypothesis that in
the TNF/GalN model in£ammation occurs prior to apoptosis
induction in hepatocytes, while in the TNF/ActD and anti-Fas
model direct apoptosis of hepatocytes is evoked. In order to
study cells and mediators involved in the TNF/GalN model,
we applied inhibitors of platelets, thromboxanes and comple-
ment. Application of several chemically di¡erent drugs con-
fers protection and illustrates that in the GalN model many
more factors are playing a role than in the ActD or anti-Fas
models.
2. Materials and methods
2.1. Mice
C57BL/6 and DBA/2 female mice were purchased from I¡a-Credo
(Saint Germain-sur-l’Arbresle, France). C3-de¢cient mice were gener-
ated by gene targeting by Dr. H.R. Colten (Washington University
School of Medicine, St. Louis, MA, USA) [14]. All mice were kept in
a conventional, air-conditioned animal house, in 12-h light/dark
cycles, and received food and water ad libitum. Mice were used at
the age of 8 weeks (20 g).
2.2. Reagents
Recombinant murine TNF was produced and puri¢ed in our labo-
ratory. It had a speci¢c activity of 1.3U108 IU/mg and contained 1.8
ng of endotoxin per mg protein, as assessed by a chromogenic sub-
strate test (Chromogenix, Stockholm, Sweden). An agonistic hamster
anti-mouse Fas monoclonal antibody was purchased from PharMin-
gen (San Diego, CA, USA) and had an endotoxin contamination of
0.05 ng/mg protein. GalN, DMSO, ActD, verapamil and tannic acid
were from Sigma Chemical Co. (St. Louis, MA, USA). Picotamide
and K76COOH were kindly provided by Dr. M. Milani (Sandoz,
Milano, Italy) and Dr. W. Miyazaki (Otsuka Pharmaceuticals, Osaka,
Japan), respectively.
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2.3. Injections and blood collections
All reagents were diluted in low endotoxin PBS prior to injection
except for picotamide, which was dissolved and injected in sterile
DMSO, and K76COOH, which was dissolved in sterile 50 mM
Tris^HCl pH 8. I.p. injections had a volume of 0.5 ml, except for
DMSO, which was injected in a 0.1 ml volume. Blood samples were
obtained by retro-orbital bleeding under light ether anesthesia.
2.4. Analysis of serum alanine aminotransferase (ALT)
Serum ALT was measured using a colorimetric assay from Sigma
Chemical Co.
2.5. Evaluation of liver apoptosis
Apoptosis was quanti¢ed either in a cell death ELISA kit according
to the manufacturer’s instructions (Roche Molecular Biochemicals,
Basel, Switzerland) or by evaluating DNA ladder patterns after agar-
ose gel electrophoresis. Samples were prepared as follows: mice were
anesthetized and dissected; the liver was perfused for 10 s with 50 mM
phosphate/120 mM NaCl/10 mM EDTA, pH 7.4 bu¡er. A 20% ho-
mogenate was made in perfusion bu¡er with a homogenizer (Hei-
dolph-Elektro, Kelheim, Germany; model RZR 2020, position II-
10) and centrifuged at 13 000Ug for 20 min. Cell death ELISA was
based on the principle of sandwich ELISA. Brie£y, plates were coated
with an anti-DNA antibody; as an Ag source the cytosolic fraction of
25 Wg of liver was used. An anti-DNA peroxidase-conjugated anti-
body was used as a second antibody. The absorbance for apoptotic
controls was regarded as 100%. The percentage of apoptosis was
calculated as follows: (Asample3Ablank)/(Acontrol3Ablank)U100. For gel
electrophoresis, DNA was prepared from 500 Wl of liver homogenate.
The proteins were extracted with phenol/chloroform/isoamyl alcohol
(50/49/1) and subsequent chloroform/isoamyl alcohol (50/50) extrac-
tion. DNA was precipitated overnight with 5 M ammonium acetate
and ethanol at 320‡C. DNA was dissolved in TE bu¡er containing
RNase. DNA was run on a 1.8% agarose gel and stained with ethi-
dium bromide.
2.6. Statistics
Mean values and S.D. were compared using an unpaired Student’s
t-test. Survival curves (Kaplan-Meier plots) were evaluated with a log
rank test; ¢nal survival was determined with a chi2 test.
3. Results
3.1. Protection against TNF/GalN-induced lethality
In C57BL/6 mice, the LD100 of murine TNF in combination
with 20 mg GalN is reached with as little as 0.1 Wg TNF per
mouse [15]. To evaluate protection by chemical drugs, we
routinely use a dose of 0.5 Wg TNF per mouse and 20 mg
GalN (5ULD100). In preliminary experiments, we ¢rst estab-
lished the minimal dose and optimal time point needed to
protect. Minimal doses were 1 mg, 10 mg, 10 mg and 7.5
mg, whereas optimal time points were 34 h, 32 h, 32 h
and 33 h for verapamil, tannic acid, picotamide and
K76COOH, respectively. When other doses and time points
were used, protection against lethality was less clear or lack-
ing, indicating that a tight schedule of dose and time of ad-
ministration is required.
In Fig. 1A^C, survival curves are shown of mice pretreated
with verapamil, tannic acid and picotamide, or solvents, and
challenged with 0.5 Wg TNF/20 mg GalN or 0.1 Wg TNF/20
mg GalN in the case of picotamide pretreatment, where no
protection was observed against 0.5 Wg TNF/20 mg GalN
(data not shown). These experiments illustrate that all three
products conferred signi¢cant (P = 0.001, 0.002 and 0.008 for
the three drugs, respectively) protection in this model. Diltia-
zem and nicardipine, calcium-channel blockers like verapamil,
were tested in di¡erent doses and schedules, but had no pro-
tective ability whatsoever (results not shown). To exclude an
endotoxin-induced tolerance due to possible endotoxin con-
tamination of the solutions used, the experiments were also
performed in endotoxin-resistant C3H/HeJ mice, and similar
results were obtained (data not shown).
Fig. 2 shows the protection conferred by K76COOH, when
Fig. 1. Protection by verapamil (A), tannic acid (B) and picotamide
(C) against a lethal challenge of TNF/GalN. Mice were pretreated
with verapamil (1 mg, 34 h), tannic acid (10 mg, 32 h) or picota-
mide (10 mg, 32 h) i.p. and challenged with 0.5 Wg TNF/GalN (ve-
rapamil, tannic acid) or 0.1 Wg TNF/GalN (picotamide). Lethality
was assessed over a period of 72 h (no further deaths occurred).
Groups and P values were: (A) eight controls, 12 verapamil
(P6 0.001); (B) eight controls, eight tannic acid (P = 0.0019); (C)
seven controls, seven picotamide (P = 0.0075). All data are pooled
results of two experiments.
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given 3 h prior to 0.5 Wg TNF/GalN. K76COOH signi¢cantly
(P6 0.0001) protects C57BL/6 mice (Fig. 2A) as well as com-
plement factor C3-de¢cient mice (P = 0.0003) (Fig. 2B), which
demonstrates that the target of K76COOH in this model is
not the complement convertase. Similar results were obtained
using C5-de¢cient DBA/2 mice (results not shown). None of
the four drugs was able to confer any protection against
LD100 of TNF+ActD or anti-Fas, when applied at the same
doses and administration schedules as in the TNF/GalN mod-
el (Table 1).
3.2. E¡ect of the inhibitors on serum ALT
6 h after injection of mice with TNF/GalN, very high values
of ALT and aspartate aminotransferase are detected. The
ALT values usually reach 2000^3000 U/l, illustrating fulmi-
nant necrosis in the liver. To evaluate the e¡ect of the drugs
on ALT release, mice were pretreated with verapamil, picota-
mide, tannic acid and K76COOH, or solvents, and challenged
with 0.5 Wg TNF/20 mg GalN or 0.1 Wg TNF/20 mg GalN
(for verapamil-pretreated mice and controls). 6 h after the
challenge, blood was withdrawn at the retro-orbital plexus
for serum preparation and consequent ALT determination.
As shown in Fig. 3, pretreatment of mice with a protective
dose of verapamil, tannic acid or picotamide signi¢cantly re-
duced the serum ALT levels (Fig. 3, P values). Tannic acid
was most potent in inhibiting ALT release. In contrast,
K76COOH, although always signi¢cantly protecting against
a lethal outcome, does not reduce, but even increases serum
ALT values (Fig. 3).
3.3. E¡ects of the drugs on liver apoptosis
To analyze the e¡ect of the drugs on TNF/GalN-induced
apoptosis of hepatocytes, livers were excised 6 h after the
challenge (from the same mice) and the amount of apoptosis
was evaluated using an apoptosis-speci¢c ELISA system. The
mean value of apoptotic samples was regarded as 100%;
apoptosis of samples was determined as described in Section
2. A protective dose of all four inhibitors proved to inhibit the
occurrence of apoptosis in the liver. As illustrated in Fig. 4A,
verapamil, tannic acid and picotamide pretreatment almost
Fig. 2. Protection by K76COOH in wild-type C57BL/6 mice (A)
and in C30=0 mice (B). Mice were pretreated with K76COOH
(7.5 mg, 33 h) or PBS (0.5 ml, 33 h) and challenged with 0.5 Wg
TNF/GalN. Lethality was assessed over a period of 72 h (no further
deaths occurred). Groups and P values were: (A) 15 controls,
14 K76COOH (P6 0.0001); (B) 10 controls, 10 K76COOH
(P6 0.0003).
Table 1
Lack of protective e¡ect of verapamil, tannic acid, picotamide or
K76COOH in other models of acute lethal hepatitis











a0.1 Wg TNF+20 Wg ActD were injected together i.p. Anti-Fas
(10 Wg) was given i.v.
bDoses and schedules were as described in the legends to Figs. 1
and 2.
cScored after 20 h in the TNF/ActD model and after 4 h in the
anti-Fas model.
Fig. 3. E¡ect of verapamil, tannic acid, picotamide and K76COOH
on TNF/GalN-induced serum ALT levels. Mice were pretreated
with verapamil (1 mg, 34 h), tannic acid (10 mg, 32 h), picotamide
(10 mg, 32 h) or K76COOH (7.5 mg, 33 h) and challenged with
0.5 Wg TNF/GalN (verapamil, tannic acid, K76COOH) or 0.1 Wg
TNF/GalN (picotamide). Mice were bled 6 h after the challenge and
ALT was measured. Group sizes and P values were: three controls,
three verapamil (P = 0.0146); ¢ve controls, three tannic acid
(P = 0.0003); six controls, six picotamide (P = 0.0442); ¢ve controls,
¢ve K76COOH (P = 0.1085).
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completely prevented apoptosis and K76COOH reduced
apoptosis by 60%. These data were con¢rmed when apoptosis
was evaluated by extracting DNA and visualization of ladder
patterns (Fig. 4B).
4. Discussion
The study of the induction of liver destruction by TNF and
members of the TNF receptor superfamily, such as Fas, has
become exceedingly popular as it was found to be preceded by
the induction of apoptosis of hepatocytes. Liver cell necrosis
has proven to be one of the dose-limiting toxicities in clinical
trials with TNF and was also recognized as a life-threatening
complication in endotoxic shock, largely mediated by cyto-
kines such as TNF [4,16]. Moreover, induction of liver ne-
crosis by alcohol [5] or even by hepatitis B virus [17] was
found to correlate with increased TNF levels. Identi¢cation
and inhibition of the key players is therefore needed to in-
crease the therapeutic value of TNF and to e⁄ciently cure
other diseases with liver necrosis complications.
Several model systems have been developed in mice, in
which liver necrosis develops after a bolus injection of (a)
TNF in combination with GalN [18], (b) TNF with ActD
[8], an anti-Fas agonistic antibody [11] and, recently, (c) con-
canavalin A [19]. The ¢rst model has been studied in detail by
several groups [15,20^22]. It was found that a number of
drugs were able to inhibit liver apoptosis and secondary ne-
crosis in this model, but not in the second and third models
[9]. Amongst these inhibitors are serine protease inhibitors (B.
Wielockx, unpublished data) and a PAF receptor antagonist
[12], illustrating that one or more serine proteases and PAF
play a pivotal role in this model, and that, in contrast to the
other models, the TNF/GalN model involves induction of
in£ammation as well as apoptosis in the liver. Also in the
TNF/GalN model, very pronounced lymphopenia and neutro-
philia were observed [23], a great number of polymorphonu-
clear cells being attached to the portal and arterial endothe-
lium in the liver (our unpublished results). Although we
previously reported that WEB2170, a PAF receptor antago-
nist, protects in the TNF/GalN model [12], we were uncertain
about the role of PAF and therefore continued to search for
more protective drugs.
Verapamil is a well-known calcium-channel antagonist of
the phenylalkylamine group, used to treat cardiovascular dis-
eases [24]. We found that this drug conferred signi¢cant pro-
tection against TNF/GalN-induced apoptosis, transaminase
release and lethality. Such protective e¡ects were not observed
using nicardipine or diltiazem, from the dihidropyridine and
benzothiazepine group, respectively. Comparable di¡erences
in response between these three calcium-channel blockers
were found in the inhibition of platelet aggregation, which
was much more outspoken in the case of verapamil [25]. We
believe that these data, but also our previous data obtained
with the platelet aggregation-inhibiting K1 acid glycoprotein
[26] suggest that platelet aggregation plays an important role
in this model. Activation of platelets may cause release of
thromboxane A2 (Tx-A2), which again stimulates platelets
in an autocrine fashion. Activated Kup¡er cells can also re-
lease Tx-A2, but depletion of these cells using gadolinium
chloride had no protective e¡ect in our models (unpublished
results). Picotamide, a speci¢c Tx-A2 antagonist [27], was
found to inhibit signi¢cantly the e¡ects of TNF/GalN. How-
ever, the protective power of picotamide was clearly inferior
compared to the other drugs, since no protection was ob-
served against a higher dose of TNF/GalN (data not shown).
We believe that these data indicate that Tx-A2 may play a
role in propagating the in£ammatory response, but that other
phenomena are of relatively greater importance. An involve-
ment of platelet activation in the GalN model has been sug-
gested before and was found to be a protective response using
a platelet-depleting antibody [28].
The protective capacity of K76COOH was initially studied
because, by comparing the sensitivity to TNF/GalN of di¡er-
ent inbred strains of mice, we believed that activation of the
complement system played an important role. K76COOH is a
Fig. 4. Protective e¡ect of verapamil, tannic acid, picotamide and
K76COOH on TNF/GalN-induced apoptosis in the liver. Mice were
pretreated with verapamil (1 mg, 34 h), tannic acid (10 mg, 32 h),
picotamide (10 mg, 32 h) or K76COOH (7.5 mg, 33 h) and chal-
lenged with 0.5 Wg TNF/GalN (verapamil, tannic acid, K76COOH)
or 0.1 Wg TNF/GalN (picotamide). Livers were excised 6 h after the
challenge. A: Apoptosis was quanti¢ed using apoptosis-speci¢c ELI-
SA. Group sizes and P values were: three controls, three verapamil
(P = 0.0068); ¢ve controls, three tannic acid (P = 0.0076); four con-
trols, four picotamide (P = 0.0008); six controls, six K76COOH
(P6 0.0001). B: Apoptosis was evaluated by agarose gel electropho-
resis and staining with ethidium bromide: mice were treated with
0.5 Wg TNF/GalN and pretreated with PBS (lanes 1 and 2), verapa-
mil (lanes 3 and 4), tannic acid (lanes 5 and 6), picotamide (lanes 7
and 8) or K76COOH (lanes 9 and 10).
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quite strong inhibitor of C5 as well as C3 convertases and has
proven to be e¡ective in prolonging survival in models of
interspecies xenograph transplantation, experimental immune
complex glomerulonephritis and ulcerative colitis [29]. We
found that K76COOH protected very well against TNF/
GalN-induced apoptosis and lethality, but that ALT values
are not reduced. So far, we have no explanation for this ap-
parent contradiction, but the data seem to indicate that mice
manage to survive because apoptosis is inhibited, although
necrosis still occurs. By a¡ecting the complement,
K76COOH may also lead to reduced formation of reactive
oxygen species (ROS), being the mechanism of protection.
This is rather unlikely, since we also found that C3-de¢cient
mice, which are still fully responsive to TNF/GalN [30],
though completely devoid of complement activation [14],
can still be protected by K76COOH. These data suggest
that the target of K76COOH is not a complement convertase.
Involvement of ROS can be further excluded, since other in-
hibitors of ROS formation, such as allopurinol and SOD, fail
to confer any protection in the TNF/GalN model (unpub-
lished data). Other activities of K76COOH are inhibition of
histamine release from mast cells and inhibition of neutrophil
activation [29]. It has been shown that neutrophils play a
central role in TNF-induced hepatitis [31]. As picotamide,
verapamil and K76COOH act on neutrophils, it is possible
that besides platelets also neutrophils play an important role
in the TNF/GalN model. Tannic acid, ¢nally, has been shown
to inhibit the induction of apoptosis in cultures of endothelial
cells by a variety of agents [32]. We found that it also protects
in our model of acute lethal hepatitis, but believe the mecha-
nism is not at the level of apoptosis of hepatocytes, since we
found no protection in the ActD or anti-Fas models. Indeed,
none of the four inhibitors mentioned here was able to protect
in the TNF/ActD or anti-Fas model. This may be ascribed to
direct apoptosis of hepatocytes in these models, while in the
GalN model also in£ammation is induced; the latter phenom-
enon leads to release of a number of harmful mediators
which, together with TNF, eventually cause apoptosis and
secondary necrosis. A further step to investigate the involve-
ment of in£ammation in the TNF/GalN model could be by
studying the activation of the proin£ammatory transcription
factor NF-UB and secretion of, for example, soluble ICAM-I,
which will be undertaken in the near future. We believe that
application of the drugs described here, alone or in combina-
tion therapy, may lead to an e⁄cient treatment of in£amma-
tory liver disorders and might increase the therapeutic value
of TNF in the treatment of cancer.
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